FDA Approves Nivolumab in Combination with Chemotherapy for Metastatic Gastric Cancer and Oesophageal Adenocarcinoma
Evidence for efficacy is based on the results from the CHECKMATE-649 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1650 results
The IGCCCG Update Model Allows Improved and More Granular Individual Prognostic Assessment in Metastatic Non-Seminomatous Germ Cell Tumours
It includes age and lung metastases as additional adverse prognostic factors and uses a single cut-off of LDH at 2.5× ULN
Percentage of Cancer Patients Who Are Eligible for and Respond to Genome-Targeted Therapy Modestly Increased Over Time
A new analysis from US show that response to genome-targeted therapy increased from 2.73% in 2006 to 7.04% in 2020
FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer
Evidence for efficacy and safety is based on the results from the TROPHY study
FDA Approves New Dosing Regimen for Cetuximab
Approval is based on population pharmacokinetic modelling analyses
FDA Grants Regular Approval to Sacituzumab Govitecan for Advanced Triple-Negative Breast Cancer
Efficacy and safety were evaluated in the ASCENT study
EMA Recommends Granting a Marketing Authorisation for Duvelisib
PI3K inhibitor is intended for the treatment of relapsed or refractory chronic lymphocytic leukaemia and refractory follicular lymphoma
Low-Dose Aspirin Could be an Alternative to Colectomy for Preventing Colorectal Cancer in FAP
Findings from a randomised J-FAPP Study IV in patients with familial adenomatous polyposis
FDA Approves Idecabtagene Vicleucel for Multiple Myeloma
Idecabtagene vicleucel is a BCMA-directed genetically modified autologous CAR T-cell therapy
Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal Junction Cancer
The CheckMate 577 study results show double longer disease-free survival with adjuvant nivolumab after neoadjuvant chemoradiotherapy and resection
EMA Recommends Extension of Indications for Enzalutamide
New indication concerns the treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy
Delayed irAEs Occur in a Small Subset of Patients with Melanoma, but Often High Grade and Difficult to Manage
Further work is needed to identify patients who are most at risk of delayed immune-related adverse events to anti-PD1 therapy